Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Schwartzberg

Showing results (11-20 of 112) with videos related to

Pageof 12
Sort By:
The American Journal of Medicine|August 28, 2024
Onco-Primary Care of Patients Receiving Immune Checkpoint InhibitorsChristopher J Hoimes, Suzanne McGettigan, Lee Schwartzberg
Cancer Management and Research|July 18, 2018
Recent advances in antiemetics: new formulations of 5HT<sub>3</sub>-receptor antagonistsJames Gilmore, Steven D'Amato, Niesha Griffith, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 22, 2017
Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK<sub>1</sub>) receptor antagonistsSnežana M Bošnjak, Richard J Gralla, Lee Schwartzberg
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 28, 2019
Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)Sally Baron-Hay, Matti Aapro, Alberto Bernareggi, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Precision Oncology: Who, How, What, When, and When Not?Lee Schwartzberg, Edward S Kim, David Liu, et al.
Journal of Oncology Practice|September 3, 2011
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptionsSonya Blesser Streeter, Lee Schwartzberg, Nadia Husain, et al.
Journal of Pain and Symptom Management|March 28, 2006
Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluationBarry Fortner, Scott Baldwin, Lee Schwartzberg, et al.
The American Journal of Managed Care|June 30, 2011
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptionsSonya Blesser Streeter, Lee Schwartzberg, Nadia Husain, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 30, 2011
Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomitingLee Schwartzberg, James Jackson, Gagan Jain, et al.
Journal of Pain and Symptom Management|December 5, 2003
The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patientsBarry Fortner, Ted Okon, Lee Schwartzberg, et al.
Pageof 12

Showing results (11-20 of 112) with videos related to

Sort By:
Pageof 12
The American Journal of Medicine|August 28, 2024
Onco-Primary Care of Patients Receiving Immune Checkpoint InhibitorsChristopher J Hoimes, Suzanne McGettigan, Lee Schwartzberg
Cancer Management and Research|July 18, 2018
Recent advances in antiemetics: new formulations of 5HT<sub>3</sub>-receptor antagonistsJames Gilmore, Steven D'Amato, Niesha Griffith, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 22, 2017
Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK<sub>1</sub>) receptor antagonistsSnežana M Bošnjak, Richard J Gralla, Lee Schwartzberg
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 28, 2019
Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)Sally Baron-Hay, Matti Aapro, Alberto Bernareggi, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Precision Oncology: Who, How, What, When, and When Not?Lee Schwartzberg, Edward S Kim, David Liu, et al.
Journal of Oncology Practice|September 3, 2011
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptionsSonya Blesser Streeter, Lee Schwartzberg, Nadia Husain, et al.
Journal of Pain and Symptom Management|March 28, 2006
Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluationBarry Fortner, Scott Baldwin, Lee Schwartzberg, et al.
The American Journal of Managed Care|June 30, 2011
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptionsSonya Blesser Streeter, Lee Schwartzberg, Nadia Husain, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 30, 2011
Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomitingLee Schwartzberg, James Jackson, Gagan Jain, et al.
Journal of Pain and Symptom Management|December 5, 2003
The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patientsBarry Fortner, Ted Okon, Lee Schwartzberg, et al.
Pageof 12